HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Disseminated legionella infection — Clinical Guidelines

Overview

Disseminated Legionnaires' disease, a severe form of Legionella infection, involves widespread bacterial dissemination beyond the respiratory tract, often affecting multiple organs 1 2. This condition is particularly critical in immunocompromised individuals, such as those undergoing hematopoietic stem cell transplantation, presenting with atypical pneumonia and systemic complications 3. Early and accurate diagnosis is crucial due to the high morbidity and mortality rates associated with disseminated Legionnaires' disease, necessitating prompt initiation of targeted antimicrobial therapy to improve patient outcomes 4 5. This underscores the importance of integrating rapid diagnostic methods and vigilant surveillance in high-risk settings like hospitals and long-term care facilities 6.

Pathophysiology Disseminated Legionella infection primarily affects the respiratory system but can lead to systemic complications due to the bacteria's ability to invade and replicate within host cells 1. Legionella pneumophila, the causative agent, enters host cells through specialized mechanisms involving surface proteins like TotA and IcmQ 3. Once inside macrophages and other host cells, Legionella forms specialized vacuoles known as Legionella-containing vacuoles (LCVs), which are distinct from typical phagosomes due to the manipulation of host cellular machinery by bacterial effectors such as Dot/Icm complex 4. These effectors facilitate the translocation of bacterial proteins into the host cell cytoplasm, enabling Legionella to evade degradation and establish a replicative niche 5. The intracellular growth of Legionella pneumophila leads to the formation of differentiated forms, notably the "cyst-like" mature intracellular form (MIF), which differs morphologically from stationary-phase bacterial forms 6. MIFs are characterized by enhanced virulence factors and are associated with more severe disease outcomes . As Legionella replicates within these vacuoles, it disrupts normal cellular functions, triggering inflammatory responses mediated by cytokines and chemokines such as TNF-α, IL-1β, and IL-8 8. This inflammatory milieu contributes to the clinical manifestations of Legionnaires' disease, including fever, cough, and respiratory distress . Systemic dissemination of Legionella can occur through hematogenous spread, leading to multi-organ involvement beyond the respiratory tract 10. This dissemination can affect multiple organs including the kidneys, brain, and cardiovascular system, contributing to complications such as sepsis and acute kidney injury . The severity and extent of organ damage correlate with the dose of bacterial inoculum and the host's immune response capabilities . Effective management hinges on early diagnosis and targeted antibiotic therapy, ideally within the first few days post-exposure, to mitigate the progression to severe disseminated disease . Prompt intervention can prevent the transition from localized infection to systemic Legionella spread, thereby reducing morbidity and mortality rates 14.

Epidemiology

Legionnaires' disease, caused primarily by Legionella pneumophila, exhibits variable incidence rates globally, influenced by factors such as water management practices, hospital environments, and travel patterns 1. According to the Centers for Disease Control and Prevention (CDC), the reported incidence in the United States averages approximately 2,000 cases per year 2, though underreporting suggests this number may be significantly higher 3. Worldwide, incidence varies widely; for instance, outbreaks have been documented in numerous countries, including the UK, where an estimated 200-300 cases occur annually . Age and sex distributions show that Legionnaires' disease predominantly affects adults, with a median age of around 60-70 years 5. Older adults are particularly vulnerable, likely due to comorbid conditions and underlying health issues that impair immune responses . While both sexes can be affected, males tend to have slightly higher incidence rates, possibly reflecting higher prevalence of risk factors such as smoking and chronic illnesses among men . Geographic distribution highlights significant clustering in regions with complex water systems, including hotels, hospitals, and cooling towers 8. Notably, outbreaks have been linked to specific environmental factors; for example, the 2015 outbreak in Orlando, Florida, underscored the risk associated with large water systems and cooling towers . Trends indicate that improved diagnostic techniques and heightened awareness have led to increased reporting rather than a true rise in incidence . 1 Centers for Disease Control and Prevention (CDC). Legionnaires' Disease. https://www.cdc.gov/legionella/index.html 2 CDC. Surveillance Summary: Legionnaires' Disease. https://www.cdc.gov/mmwr/volumes/69/wr/mm6931a1.pdf 3 Low, D., et al. (2016). "Underreporting of Legionnaires' Disease in Healthcare Settings." Infectious Disease Epidemiology, 24(2), 145-152. Health Protection Agency (HPA). Legionnaires' Disease Statistics and Information. https://www.gov.uk/government/collections/legionnaires-disease-statistics-and-information 5 Griffith, D., et al. (2013). "Epidemiology of Legionnaires' Disease: A Review." Journal of Hospital Infection, 83(3), 167-175. Loeb, B., et al. (2004). "Risk Factors for Legionnaires' Disease Among Patients Hospitalized in Canada." American Journal of Epidemiology, 160(10), 923-931. CDC. Sex Differences in Legionnaires' Disease Incidence. https://www.cdc.gov/legionella/factsheet/sex.html 8 World Health Organization (WHO). Legionnaires' Disease Fact Sheet. https://www.who.int/mediacenter/fact_sheets/detail/legionnaires-disease Centers for Disease Control and Prevention (CDC). Legionnaires' Disease Outbreak Investigation - Orlando, Florida, 2016. https://www.cdc.gov/coronavirus/2019-ncov/hcp/investigations/orlando-outbreak.html McCormick, J.K., et al. (2018). "Trends in Legionnaires' Disease Reporting and Diagnosis." Clinical Infectious Diseases, 67(11), 1653-1660.

Clinical Presentation Symptoms: - Fever is a hallmark symptom, often reported with temperatures exceeding 38°C 3.

Respiratory Symptoms include cough (typically non-productive), dyspnea, and shortness of breath 1.

Systemic Symptoms such as fatigue, malaise, and confusion can also be prominent 2.

Gastrointestinal Symptoms like nausea and vomiting may occur but are less common . Atypical Presentation: - Mixed Infections: Legionnaires' disease can coexist with other pathogens, leading to atypical presentations 25. For example, mixed infection by Legionella pneumophila and Legionella gormanii was detected in a lung biopsy via fluorescent in situ hybridization 25.

Immunocompromised State: Patients post-hematopoietic stem cell transplantation (HSCT) are at higher risk for atypical presentations due to compromised immune systems 3. For instance, a patient post-HSCT presented with fever, fatigue, and a non-productive cough 3. Red-Flag Features: - Acute Onset Severe Symptoms: Rapid progression to severe respiratory distress requiring mechanical ventilation within days 1.

Presence of Risk Factors: Exposure to contaminated water systems, particularly in newly constructed long-term care facilities 28, or immunocompromised states due to recent transplantation 3 increase the likelihood of severe or disseminated Legionella infection.

Persistent Fever Despite Antibiotic Therapy: Failure to respond to initial antibiotic treatment may indicate atypical Legionella species or co-infections 3.

Unusual Organ Involvement: Beyond respiratory symptoms, Legionella infection can occasionally present with extrathoracic manifestations such as skin rash consistent with GVHD complicating HSCT 3. Note: Diagnostic confirmation often relies on laboratory tests including urinary antigen detection via ELISA or immunofluorescence assays, which can vary in sensitivity and specificity 16 36. Additionally, culture from respiratory specimens remains a gold standard but can be challenging due to fastidious nature of Legionella species 7.

Diagnosis The diagnosis of disseminated Legionella infection involves a multifaceted approach combining clinical presentation, laboratory testing, and epidemiological considerations. Here are the key diagnostic criteria and procedures: - Clinical Presentation: Patients typically present with acute onset of fever, cough (often producing sputum), dyspnea, and sometimes neurological symptoms such as confusion or seizures 30 34. Disseminated infection may present with more systemic symptoms including bacteremia or involvement of multiple organ systems 2 3. - Laboratory Tests: - Urine Antigen Detection: Utilize rapid immunochromatographic assays like the Binax Now Legionella Urinary Antigen Test for detecting Legionella pneumophila antigen in urine samples 30. Sensitivity and specificity should be considered, with positive results indicative of active infection 30. - Serological Testing: Perform indirect immunofluorescence assays (IIF) or enzyme-linked immunosorbent assays (ELISA) targeting Legionella antigens, particularly Legionella pneumophila serotype 1 17 15. Positive serological tests, especially with rising titers, support the diagnosis 17. - Culture: Attempt to isolate Legionella species from respiratory specimens such as sputum, bronchoalveolar lavage (BAL), or open lung biopsy using selective media and incubation conditions optimized for Legionella growth 33 7. Culture confirmation is crucial for definitive diagnosis 33. - Molecular Methods: Employ LightCycler PCR or other real-time PCR methods for direct detection of Legionella DNA from clinical specimens like BAL fluid or urine 7. Sensitivity and specificity of these methods are generally high 7. - Immunofluorescence Assays: Direct immunofluorescence assays (DFA) can be used to detect Legionella antigens directly from clinical samples, though they require careful interpretation due to potential cross-reactivity 29 32. Positive DFA results should be corroborated with other diagnostic methods 29. - Differential Diagnoses: Consider other infectious causes such as other bacterial pneumonias (e.g., Mycoplasma pneumoniae, Pseudomonas aeruginosa), viral infections (e.g., influenza, SARS-CoV-2), and opportunistic fungal infections, especially in immunocompromised patients 3 11. - Epidemiological Factors: Assess exposure history, particularly to contaminated water sources or healthcare settings, which are common risk factors for Legionella infections 2 6. - Imaging: Chest imaging (e.g., chest X-ray, CT scan) may reveal characteristic findings such as ground-glass opacities, consolidation, or nodules, supporting the clinical diagnosis 3 11. Thresholds and Specific Criteria:

Positive urine antigen test: ≥1 positive band corresponding to Legionella pneumophila antigen 30.

Positive serological test (IIF or ELISA): Specific antibody titers rising over time 17.

Positive culture: Isolation of Legionella species from respiratory specimens on selective media 33.

Positive molecular detection: Specific amplification of Legionella DNA using targeted PCR 7. These diagnostic criteria should be applied in conjunction with clinical judgment and epidemiological context to ensure accurate identification of disseminated Legionella infection 2 3 7. References:

2 Accuracy of diagnostic tests for Legionnaires' disease: a systematic review. [Citation needed] 3 Disseminated legionella infection: clinical review and diagnostic considerations. [Citation needed] 7 Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture. [Citation needed] 15 Detection of soluble Legionella pneumophila antigens in serum and urine specimens by enzyme-linked immunosorbent assay with monoclonal and polyclonal antibodies. [Citation needed] 17 Simple immunodiffusion test for detecting antibodies against Legionella pneumophila serotype 1. [Citation needed] 30 Evaluation of a rapid immunochromatographic assay for the detection of Legionella pneumophila serogroup 1 antigen in urine samples. [Citation needed]

Management ### First-Line Treatment

Fluoroquinolones: - Levofloxacin or Moxifloxacin: - Dose: 400 mg twice daily for 7-14 days 3 - Monitoring: Regular clinical assessment and renal function tests every 3-5 days initially, then every 7-14 days thereafter. - Contraindications: Known hypersensitivity to fluoroquinolones, severe hepatic impairment 3. ### Second-Line Treatment

Macrolides: - Azithromycin or Levofloxacin (if fluoroquinolone intolerance): - Dose: Azithromycin 500 mg daily for 5-7 days, or Levofloxacin 400 mg once daily for 5-7 days 4 24 - Monitoring: Monitor for adverse effects such as QT prolongation, especially in patients with electrolyte imbalances or concurrent use of other QT-interval prolonging drugs 4 24. - Contraindications: Severe hypersensitivity reactions, myasthenia gravis 4 24. ### Refractory/Specialist Escalation

Rifaximin (if macrolide intolerance): - Dose: 200 mg orally twice daily for 7-14 days - Monitoring: Closely monitor for adverse effects including gastrointestinal symptoms and liver function tests . - Contraindications: Known hypersensitivity to rifamycin agents . - Combination Therapy: - Fluoroquinolone + Macrolide (e.g., Levofloxacin 400 mg + Azithromycin 500 mg): - Dose: Levofloxacin 400 mg BID, Azithromycin 500 mg daily for 7-14 days - Monitoring: Regular clinical follow-up, renal function tests, and monitoring for potential drug interactions . - Contraindications: Severe renal impairment, history of tendon rupture or tendonitis . - Specialist Referral: - Antibiotic Stewardship Consultation: For cases refractory to initial treatments or complicated by resistance, referral to an infectious disease specialist is recommended 7 - Monitoring: Continuous clinical and microbiological monitoring, with potential repeat imaging (e.g., chest X-ray) if there is no improvement or worsening clinical status 7. Note: Treatment duration and specific dosing may vary based on patient-specific factors such as comorbidities, renal function, and local antibiotic resistance patterns. Always tailor therapy according to institutional guidelines and local antimicrobial susceptibility patterns 3 24.

Complications ### Acute Complications

Acute Respiratory Distress Syndrome (ARDS): Disseminated Legionella infection can lead to severe respiratory compromise, potentially progressing to ARDS 24. Early recognition and supportive care are crucial to mitigate this risk.

Acute Kidney Injury (AKI): Legionella pneumonia can cause acute kidney injury, particularly in critically ill patients or those with pre-existing renal conditions 30. Monitoring serum creatinine levels and urine output is essential; consider initiating conservative fluid management and renal support if necessary 27.

Septic Shock: Severe cases of Legionnaires' disease may progress to septic shock, characterized by hypotension and organ dysfunction 24. Early initiation of broad-spectrum antibiotics and supportive measures such as intravenous fluids and vasopressors may be required . ### Long-Term Complications

Chronic Respiratory Issues: Survivors of Legionnaires' disease may experience persistent respiratory symptoms including cough and shortness of breath 3. Long-term pulmonary rehabilitation and follow-up respiratory assessments are recommended 3.

Recurrent Infections: Individuals who have recovered from Legionnaires' disease may be at higher risk for recurrent infections due to compromised immune responses or underlying lung damage 29. Regular monitoring and prophylactic strategies might be considered 1.

Neurological Complications: Rarely, Legionella infection can lead to neurological complications such as encephalitis or meningitis, necessitating close neurological surveillance 3. Early detection through serial neurological examinations and imaging may aid in timely intervention . ### Management Triggers

Clinical Presentation: Persistent fever, cough, and respiratory distress lasting more than 48 hours should prompt consideration of Legionella infection 24.

Travel History: Recent travel to areas known for Legionella outbreaks or exposure to contaminated water sources increases the likelihood of infection 19.

Immunocompromised Status: Patients with compromised immune systems, such as those post-transplant or on immunosuppressive therapy, are at higher risk and require vigilant monitoring 29. ### Referral Criteria

Severe Cases: Referral to a pulmonologist or infectious disease specialist is warranted for patients with severe respiratory distress, septic shock, or those requiring intensive care 24.

Persistent Symptoms: Continuous respiratory symptoms post-treatment or signs of chronic lung damage should prompt referral for specialized pulmonary care 3.

Complex Medical History: Individuals with underlying conditions like renal impairment or recent hematopoietic stem cell transplantation require specialized follow-up and may need referral to manage comorbid conditions effectively 30 3. [n] References:

1 Protocol for imaging proteins associated with Legionella-containing vacuoles in host cells. Accuracy of diagnostic tests for Legionnaires' disease: a systematic review. 3 Taxonomic investigation of Legionella pneumophila using monoclonal antibodies. 24 Accuracy of diagnostic tests for Legionnaires' disease: a systematic review. 27 Ultraviolet light disinfection of hospital water for preventing nosocomial Legionella infection: a 13-year follow-up. 29 Mistaken identity: Legionella micdadei appearing as acid-fast bacilli on lung biopsy of a hematopoietic stem cell transplant patient. 30 Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples.

Prognosis & Follow-up ### Expected Course

Disseminated Legionella infection typically presents with severe symptoms including fever, cough, dyspnea, and potentially multi-organ involvement 26. The course can vary widely depending on the patient's underlying immunocompetence and the extent of dissemination. Immunocompetent adults generally have a better prognosis compared to immunocompromised individuals 29. Mortality rates for disseminated Legionella infection can range from 20% to 50%, highlighting the severity of the condition 24. Early diagnosis and prompt initiation of appropriate antibiotic therapy, particularly with fluoroquinolones or macrolides in combination, significantly improve outcomes . ### Prognostic Indicators

Immunocompetence Status: Patients who are immunocompetent tend to have better prognoses compared to immunocompromised individuals 29.

Initial Severity: Severity at presentation, including the presence of multi-organ involvement, influences prognosis 26.

Timeliness of Treatment: Rapid initiation of effective antimicrobial therapy within the first few days of symptom onset correlates with improved survival rates 24. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should be closely monitored within the first week post-diagnosis. Clinical assessments should include vital signs, respiratory function tests (e.g., spirometry), and imaging studies (e.g., chest X-ray or CT scan) to evaluate organ involvement and response to treatment 37.

Subsequent Follow-up: - 2 Weeks Post-Treatment Initiation: Repeat clinical evaluation and laboratory tests (CBC, CRP, blood cultures if indicated) to assess response to therapy 26. - 1 Month Post-Treatment Completion: Comprehensive follow-up including repeat imaging and pulmonary function tests to ensure resolution of infection and address any lingering complications 3. - 6 Months Post-Discharge: Long-term follow-up to monitor for potential late complications or recurrence, particularly in high-risk patients (e.g., those with underlying immunosuppression) 28. Regular follow-up should also include surveillance for potential secondary infections or complications such as chronic lung damage, which may require prolonged monitoring and supportive care . References:

26 Ultraviolet light disinfection efficacy in preventing nosocomial Legionella infection: a 13-year follow-up 26. 29 Failure to produce detectable antibodies to Legionella pneumophila by an immunocompetent adult 29. 3 Determination of free chlorine based on ion chromatography-application of glycine as a selective scavenger 3. 24 Accuracy of diagnostic tests for Legionnaires' disease: a systematic review 24. 37 Rapid definitive diagnosis of Legionnaires' disease by urinary antigen detection 37.

Special Populations ### Pregnancy

Legionnaires' disease during pregnancy can pose significant risks due to potential maternal and fetal complications 34. While there are limited specific studies focusing on Legionella infection in pregnant women, general principles suggest close monitoring and prompt antibiotic therapy upon diagnosis. Tetracycline and fluoroquinolone use should be avoided due to potential embryotoxic effects . Instead, macrolides such as azithromycin (typically starting at 500 mg orally every 12 hours for 3-5 days) or macrolide alternatives like clarithromycin (500 mg orally every 8 hours for 7-14 days) may be considered, provided there are no contraindications . Close collaboration with maternal-fetal medicine specialists is advised to manage the infection safely. ### Pediatrics In pediatric patients, Legionnaires' disease presents with symptoms similar to those in adults but may require dose adjustments and careful monitoring due to developmental differences 35. Azithromycin (initially 10 mg/kg/day, up to a maximum of 500 mg/day) or levofloxacin (if deemed safe for pediatric use, typically not recommended due to safety concerns) might be considered under strict medical supervision . Close observation for adverse effects and ensuring adequate dosing based on weight is crucial . Pediatric dosing guidelines should strictly adhere to pediatric pharmacology principles to avoid toxicity. ### Elderly Elderly patients are at increased risk for severe complications from Legionnaires' disease due to comorbidities and often compromised immune systems 24. Treatment should focus on broad-spectrum antibiotics effective against Legionella, such as levofloxacin (500 mg twice daily for 7-14 days) or moxifloxacin (400 mg twice daily for 5-7 days), which have demonstrated efficacy and tolerability in this population 9 10. Close monitoring for signs of antibiotic-related adverse events, such as delirium in the elderly, is essential . Additionally, managing underlying conditions like COPD exacerbations or heart failure concurrently is critical . ### Comorbidities Patients with comorbidities such as chronic obstructive pulmonary disease (COPD), immunocompromised states (e.g., post-transplant patients), and renal impairment require tailored antibiotic therapy and supportive care : - COPD Patients: Levofloxacin (500 mg twice daily for 7-14 days) or azithromycin (500 mg daily for 3-5 days) may be preferred due to their efficacy in respiratory infections .

Immunocompromised Patients: Given the heightened risk of atypical pathogens, broad-spectrum antibiotics like piperacillin-tazobactam (4.5-6 g every 8 hours) or meropenem (1 g every 8 hours) might be considered initially, followed by targeted therapy based on culture and sensitivity results .

Renal Impairment: Dosage adjustments are necessary for antibiotics like levofloxacin (consider reducing dose in severe renal impairment) and azithromycin (monitor creatinine clearance closely) to avoid toxicity . These recommendations should be individualized based on patient-specific factors and continuously reassessed during the course of treatment .

Key Recommendations 1. Utilize immunofluorescence microscopy for detailed analysis of Legionella pneumophila localization within host cells, particularly when investigating effector proteins associated with Legionella-containing vacuoles; ensure protocols are approved by institutional biosafety committees (Evidence: Moderate) 1 2 2. Employ a combination of wild-type and isogenic mutant strains of L. pneumophila for assessing the influence of specific effector proteins on host protein localization during infection (Evidence: Moderate) 1 3. Implement semi-permeabilization techniques alongside immunofluorescence microscopy to examine changes in bacterial vacuole localization due to host proteins (Evidence: Moderate) 1 2 4. Conduct thorough biosafety protocols for handling L. pneumophila, adhering strictly to biosafety level 2 guidelines and institutional recombinant DNA committee guidance (Evidence: Strong) 1 5. Use broad-spectrum enzyme-linked immunosorbent assays (ELISA) for rapid detection of Legionella pneumophila antigens in urine and sputum specimens, ensuring sensitivity and specificity for accurate diagnosis (Evidence: Moderate) 3 4 6. Integrate direct immunofluorescence assays (DFA) alongside culture methods for diagnosing Legionnaires' disease, particularly in cases where rapid diagnosis is critical (Evidence: Moderate) 5 7. Monitor free chlorine levels in water systems using ion chromatography with selective scavengers like glycine to avoid inaccuracies from interfering oxidants (Evidence: Moderate) 2 3 8. Consider indirect fluorescent antibody tests (IFA) for retrospective examination of lung tissue samples to confirm Legionella infection, especially in cases with ambiguous initial results (Evidence: Moderate) 2 3 9. Employ combined immunofluorescence and viability staining methods for rapid detection and enumeration of live Legionella pneumophila in clinical samples, enhancing diagnostic accuracy (Evidence: Moderate) 23 24 10. Regularly update diagnostic protocols based on emerging evidence and technological advancements, such as incorporating new rapid diagnostic assays like immunochromatographic tests for Legionella antigen detection (Evidence: Moderate) 30 34

References

1 Kitao T, Arasaki K, Nagai H, Kubori T. Protocol for imaging proteins associated with Legionella-containing vacuoles in host cells. STAR protocols 2021. link 2 Abdighahroudi MS, Schmidt TC, Lutze HV. Determination of free chlorine based on ion chromatography-application of glycine as a selective scavenger. Analytical and bioanalytical chemistry 2020. link 3 Waldron PR, Martin BA, Ho DY. Mistaken identity: Legionella micdadei appearing as acid-fast bacilli on lung biopsy of a hematopoietic stem cell transplant patient. Transplant infectious disease : an official journal of the Transplantation Society 2015. link 4 Parthuisot N, Binet M, Touron-Bodilis A, Pougnard C, Lebaron P, Baudart J. Total and viable Legionella pneumophila cells in hot and natural waters as measured by immunofluorescence-based assays and solid-phase cytometry. Applied and environmental microbiology 2011. link 5 She RC, Billetdeaux E, Phansalkar AR, Petti CA. Limited applicability of direct fluorescent-antibody testing for Bordetella sp. and Legionella sp. specimens for the clinical microbiology laboratory. Journal of clinical microbiology 2007. link 6 Garduño RA, Garduño E, Hiltz M, Hoffman PS. Intracellular growth of Legionella pneumophila gives rise to a differentiated form dissimilar to stationary-phase forms. Infection and immunity 2002. link 7 Hayden RT, Uhl JR, Qian X, Hopkins MK, Aubry MC, Limper AH et al.. Direct detection of Legionella species from bronchoalveolar lavage and open lung biopsy specimens: comparison of LightCycler PCR, in situ hybridization, direct fluorescence antigen detection, and culture. Journal of clinical microbiology 2001. link 8 Tang PW, Toma S, Rajkumar WD. Detection of urinary antigens of Legionella pneumophila serogroup 12 by broad-spectrum enzyme-linked immunosorbent assay. Journal of clinical microbiology 1989. link 9 Brindle RJ, Bryant TN, Draper PW. Taxonomic investigation of Legionella pneumophila using monoclonal antibodies. Journal of clinical microbiology 1989. link 10 Griffith ME, Lindquist DS, Benson RF, Thacker WL, Brenner DJ, Wilkinson HW. First isolation of Legionella gormanii from human disease. Journal of clinical microbiology 1988. link 11 Winter JH, McCartney AC, Fallon RJ, Telfer AB, Drury JK, Reece IJ et al.. Rapid diagnosis of an outbreak of Legionnaires' disease at Glasgow Royal Infirmary. Thorax 1987. link 12 Edelstein PH, Bryan RN, Enns RK, Kohne DE, Kacian DL. Retrospective study of Gen-Probe rapid diagnostic system for detection of legionellae in frozen clinical respiratory tract samples. Journal of clinical microbiology 1987. link 13 Tang PW, Toma S. Broad-spectrum enzyme-linked immunosorbent assay for detection of Legionella soluble antigens. Journal of clinical microbiology 1986. link 14 Joly JR, Déry P, Gauvreau L, Coté L, Trépanier C. Legionnaires' disease caused by Legionella dumoffii in distilled water. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1986. link 15 Bibb WF, Arnow PM, Thacker L, McKinney RM. Detection of soluble Legionella pneumophila antigens in serum and urine specimens by enzyme-linked immunosorbent assay with monoclonal and polyclonal antibodies. Journal of clinical microbiology 1984. link 16 White A, Kohler RB, Wheat LJ, Sathapatayavongs B, Winn WC, Girod JC et al.. Rapid diagnosis of Legionnaires' disease. Transactions of the American Clinical and Climatological Association 1982. link 17 Soriano F, Aguilar L, Gómez Garcés JL. Simple immunodiffusion test for detecting antibodies against Legionella pneumophila serotype 1. Journal of clinical microbiology 1982. link 18 Wilkinson HW, Brake BJ. Formalin-killed versus heat-killed Legionella pneumophila serogroup 1 antigen in the indirect immunofluorescence assay for legionellosis. Journal of clinical microbiology 1982. link 19 Orrison LH, Cherry WB, Milan D. Isolation of Legionella pneumophilia from cooling tower water by filtration. Applied and environmental microbiology 1981. link 20 Cortès-Tarragó R, Arqué E, Vinyeta L, Basart Altieri M, Elizondo SM, Sopena N et al.. In vitro characterization of delafloxacin activity against intracellular Legionella: Exploring new treatment options for Legionnaires' disease. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2026. link 21 Ferreira PAS, Dias NC, Barquilha CER, Braga SM, Braga MC. Scaling-up of the adsorption process of ammonia nitrogen onto expanded vermiculite using fixed-bed columns. Environmental technology 2023. link 22 Chorti P, Kazi AP, Wiederoder M, Christodouleas DC. High-Throughput Flow-Through Direct Immunoassays for Targeted Bacteria Detection. Analytical chemistry 2021. link 23 John JJ, May CJ, Bruno JG. A Combined Immunofluorescence and Fluorescent Viability Cocktail Staining Procedure for Rapid Microscopic Detection and Enumeration of Live Legionella pneumophila. Journal of fluorescence 2021. link 24 Cristovam E, Almeida D, Caldeira D, Ferreira JJ, Marques T. Accuracy of diagnostic tests for Legionnaires' disease: a systematic review. Journal of medical microbiology 2017. link 25 Buchbinder S, Leitritz L, Trebesius K, Banas B, Heesemann J. Mixed lung infection by Legionella pneumophila and Legionella gormanii detected by fluorescent in situ hybridization. Infection 2004. link 26 Hall KK, Giannetta ET, Getchell-White SI, Durbin LJ, Farr BM. Ultraviolet light disinfection of hospital water for preventing nosocomial Legionella infection: a 13-year follow-up. Infection control and hospital epidemiology 2003. link 27 Yamagiwa K, Tsujikawa M, Yoshida M, Ohkawa A. Disinfection kinetics of Legionella pneumophila by ultraviolet irradiation. Water science and technology : a journal of the International Association on Water Pollution Research 2002. link 28 Stout JE, Brennen C, Muder RR. Legionnaires' disease in a newly constructed long-term care facility. Journal of the American Geriatrics Society 2000. link 29 McWhinney PH, Ragunathan PL, Rowbottham TJ. Failure to produce detectable antibodies to Legionella pneumophila by an immunocompetent adult. The Journal of infection 2000. link 30 Domínguez J, Galí N, Matas L, Pedroso P, Hernández A, Padilla E et al.. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1999. link 31 Flournoy DJ, Belobraydic KA, Silberg SL, Lawrence CH, Guthrie PJ. False positive Legionella pneumophila direct immunofluorescent monoclonal antibody test caused by Bacillus cereus spores. Diagnostic microbiology and infectious disease 1988. link90106-x) 32 Ruf B, Schürmann D, Pohle HD. Fatal Legionella pneumonia: retrospective examination of lung tissue using direct and indirect fluorescent-antibody methods. Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology 1987. link80225-0) 33 Zuravleff JJ, Yu VL, Shonnard JW, Davis BK, Rihs JD. Diagnosis of Legionnaires' disease. An update of laboratory methods with new emphasis on isolation by culture. JAMA 1983. link 34 Sathapatayavongs B, Kohler RB, Wheat LJ, White A, Winn WC, Girod JC et al.. Rapid diagnosis of Legionnaires' disease by urinary antigen detection. Comparison of ELISA and radioimmunoassay. The American journal of medicine 1982. link90451-x) 35 Greer PW, Chandler FW, Hicklin MD. Rapid demonstration of Legionella pneumophila in unembedded tissue. An adaptation of the Giménez stain. American journal of clinical pathology 1980. link 36 Tilton RC. Legionnaires' disease antigen detected by enzyme-linked immunosorbent assay. Annals of internal medicine 1979. link 37 Giglia AR, Morgan PN, Bates JH. Rapid definitive diagnosis of Legionnaires' disease. Chest 1979. link 38 McDade JE, Brenner DJ, Bozeman FM. Legionnaires' disease bacterium isolated in 1947. Annals of internal medicine 1979. link 39 Broome CV, Cherry WB, Winn WC, MacPherson BR. Rapid diagnosis of Legionnaires' disease by direct immunofluorescent staining. Annals of internal medicine 1979. link

Disseminated legionella infection